Search

Your search keyword '"Schatteman L"' showing total 16 results
Start Over Author "Schatteman L"
16 results on '"Schatteman L"'

3. IX Eular Workshop for Rheumatology Research: Molecular biology of autoantigens, autoantibodies and immunopeptides. Vienna, Austria, March 9–12, 1989

Author

Fournier, C., Texier, B., Chiocchia, G., Boissier, M. C., Herbage, D., Brown, C. M. S., Zyberk, C. Plater, Maini, R. N., Palacios, A., Sieper, J., Heinegard, D., Panayi, G. S., Gentric, A., Mackenzie, L., Lydyard, P. M., Youinou, P., Menzel, E. J., Kaik, B., Sykulev, Yu. K., Guschin, A. Je., Vasiljev, V. I., Ostreiko, K. K., Yeronina, T. V., Tumanova, I. A., Moynier, M., Abderrazik, M., Combe, B., Rucheton, M., Brochier, J., Tuomi, T., Palosuo, T., Heliövaara, M., Aho, K., McHugh, N. J., James, I. E., Kallenberg, C. G. M., Tervaert, J. W. Cohen, Goldschmeding, R., Von Dem Borne, A. E. G. K. R., Bouanani, M., Piechaczyk, M., Pau, B., Bastide, M., Le Page, S., Williams, W., Parkhouse, D., Cambridge, G., Isenberg, D. A., Nimmegeers, J., De Keyser, F., Verbruggen, G., Veys, E. M., Walravens M. J. F., Verdeyen I., Vandepol B., Cortens W., Schatteman, L., Goethals, K., Wu, D. -H., Tavoni, A., Neri, R., Garzelli, C., Vitali, C., Bombardieri, S., Logar, D., Kveder, T., Dobovisek, J., Rozman, B., Menard, H. A., Boire, G., Lopez-Longo, F. J., Masson, Ch., Lapointe, S., Clair, E. W. St., Zerva, L., Moutsopoulos, H. M., Keene, J. D., Pisetsky, D. S., Van Dam, A. P., Cuypers, H. T. M., Winkel, I., Smeenk, R. J. T., Taylor, D., Valente, E., Foster, J. P., Williams, D. G., Stocks, M. R., Caporali, R., De Gennaro, F., Cerino, A., Cobianchi, F., Astaldi-Ricotti, G. C. B., Montecucco, C., Habets, W., Sillekens, P. T. G., Hoet, M. H., McAllister, G., Lerner, M. R., Van Venrooij, W. J., Habets, W. J., Van Der Kemp, A., De Jong, B., Scarpa, R., Pucino, A., Di Girolamo, C., della Valle, G., Larizza, G., Casiere, D., Oriente, P., Paimela, L., Palvimo, J., Kurki, P., Hassfeld, W., Steiner, G., Graninger, W., Smolen, J. S., Lopez-Longo, E. J., Larose, A., Hoet, R., Zewald, R., Smeenk, R., Brinkman, K., Van Den Brink, H., Westgeest, A., Huss, R., Krapf, E. F., Herrmann, M., Leitmann, W., Kalden, J. R., Merétey, K., Cebecauer, L., Böhm, U., Kozakova, D., Brózik, M., Temesvári, P., Nagy, L., Bozic, B., Stegnar, M., Vene, N., Peternel, P., Giuggioli, C., Monti, P., Rossi, G., Ferri, C., Chiellini, S., Baboonian, C., Venables, P. J. W., Roffe, L., Booth, J., Krapf, F., Abuljadayel, I., Ebringer, A., Cox, N. L., Brand, S. R., McIntosh, D. P., Bernstein, R. M., Van Den Broek, M. F., Van Bruggen, M. C. J., Smetsers, T., Kuyer, P., Van De Putte, L., Van Den Berg, W. B., Toivanen, A., Jalkanen, S., Lahesmaa-Rantala, R., Isomäki, O., Pekkola-Heino, K., Merilahti-Palo Saario, R., Von Essen, R., Isomäki, H., Granfors, K., Gaston, J. S. H., Life, P. F., Bailey, L., Bacon, P. A., Khalafpour, S., Wilson, C., Awad, J., Toivanen, P., Saario, R., Skurnik, M., Van Der Straeten, C., Mielants, H., Gazic, M., Hartung, K., Riedel, T., Stannat, S., Specker, Ch., Röther, E., Pirner, K., Schendel, D., Baur, M., Corvetta, A., Peter, H. H., Lakomek, H. J., Deicher, H., Andonopoulos, A. P., Papasteriades, C. A., Drosos, A. A., Dimou, G. S., Shattles, W., Venables, P., Charles, P. J., Markwick, J. R., Venables, P. J., Galeazzi, M., Lulli, P., Tuzi, T., Cappellacci, S., Morellini, M., Trabace, S., Cutrupi, F., Sorrentino, R., Botti, S., Iannicola, C., Costanzi, S., Tosi, R., Gospodinoff, A., Eliaou, J. F., Humbert, H., Balaguer, P., Nicolas, J. C., Sany, J., Clot, J., Sakkas, L. I., Bird, H., Welsh, K. I., Pitzalis, C., Kingsley, G., Haskard, D., Vischer, T. L., Bas, S., Werner-Favre, C., Wohlwend, D., Zubler, R. H., Afeltra, A., De Pita, O., Basso, P., Pietrucci, A., Ferri, G. M., Bonomo, L., Gerli, R., Cernetti, C., Bertotto, A., Agea, E., Arcangeli, C., Lanfrancone, L., Rambotti, P., Crupi, S., Baglioni, A., Spinozzi, F., Papazoglou, S., Skoumi, D., Athanasiou, P., Iliopoulos, A., Stavropoulou, A., Kontomerkos, T., Hendrich, G., Kuipers, J. G., Hammer, M., Schmidt, R. E., Manoussakis, M. N., Germandis, G., Zerva, L. V., Siouna-Fatourou, H. J., Katsikis, P. D., Mavridis, A., Toubert, A., Sadouk, M., de la Tour, B., Vaquero, C., Amor, B., Miossec, P., Naviliat, M., Cretien, I., Banchereau, J., Graninger, P., Aschauer, B., Sinski, A., Smolen, J., Krutmann, J., Kirnbauer, R., Köck, A., Schwarz, T., May, L. T., Sehgal, P. B., Luger, T. A., Field, M., Chu, C. Q., Feldmann, M., Wilbrink, B., Nietfeld, J. J., Helle, M., Boeije, L. C. M., Van Roy, J. L. A. M., Den Otter, W., Aarden, L. A., Huber-Bruning, O., Malejczyk, J., Urbanski, A., Malejczyk, M., Karbowski, A., Völker, W., Feige, U., Otter, W. Den, Malfait, A. M., Wieme, N., Gyselbrecht, L., Van de Loo, A. A. J., Van Lent, P. L. E. M., Haskard, D. O., Wellicome, S., Lanchbury, J., Thornhill, M., Krutmann, K., Gschnait, F., Yaron, M., Yaron, I., Dayer, J. -M., Bleiberg, I., Meyer, F. -A., Maury, C. P. J., Teppo, A. -M., Salo, E., Pelkonen, P., Malfait, A., Cochez, Ph., Gruschwitz, M., Müller, P. U., Wick, G., Madhok, R., Wilson, R., Frame, M., Thompson, J., Sturrock, R. D., Partsch, G., Matucci-Cerinic, M., Marabini, S., Jantsch, S., Neumüller, J., Eberl, R., van Beuningen, H. M., Arntz, O. J., Zlabinger, G. J., Steffen, C., Brand, H. S., Van Kampen, G. P. J., De Koning, M. H. M. T., Kiljan, E., Van Der Korst, J. K., Gemmell, C. G., Swaak, A. J. G., Van Rooyen, A., Hall, N. D., Woolf, A. D., Kantharia, B., Maymo, J., Blake, D. R., Goulding, N. J., Maddison, P. J., Munthe, E., Berntzen, H. B., Fagerhol, M., Mathieu, A., Pala, R., Contu, L., Cirillo, R., Garau, P., Nurchis, P., Viberti, G. C., Meyer, O., Zenklusen, C., Le Thi Huong Du, Z., Gaudouen, C., Mery, J. Ph., Ronco, P., Kahn, M. F., Rasmussen, N., Szpirt, W., Thomsen, B., Humbel, R. L., Ter Borg, E. J., Horst, G., Hummel, E., Limburg, P. C., Aeschilmann, A., Bourgeois, P., De Rooij, D. J., Van de Putte, L. B. A., Verbeek, L., Farinaro, C., Infranzi, E., Couret, M., Ackerman, C., De Vlam, K., Carapic, V., Carapic, D., Annefeld, M., Erne, B., Rosenwasser, L. J., Pazoles, C. J., Otterness, I. G., Hanson, D. C., McDonald, B., Loose, L. D., Dougados, M., Machold, K. P., Wiesenberg-Böttcher, I., Wanner, K., Pignat, W., Altmann, H., Tuschl, H., Bröll, H., Balestrieri, G., Tincani, A., Cattaneo, R., Bertoli, M. T., Martinelli, M., Allegro, F., Meroni, P. L., Balesini, G., Aichinger, G., Schlögl, E., Huber, Ch., Shoenfeld, Y., Fleishmaker, E., Mendlovic, S., Mozes, E., Blank, M., Talal, N., Hogervorst, E. J. M., Van Eden, W., Van Der Zee, R., Psychos, D., Dimou, G., Stefanaki-Nikou, S., Papadimitriou, C. S., Settas, L., Alexiou, P., Dimitriadis, G., Mataftsi, E., Soliou, E., Tourkantonis, A., Babic, M., Jeurissen, M. E. C., and Boerbooms, A. MTh

Published
1989
Full Text
View/download PDF

8. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.

Author

Schatteman L, Gyselbrecht L, De Clercq L, and Mielants H

Subjects
Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Drug Resistance, Female, Glucocorticoids therapeutic use, Humans, Infliximab, Injections, Intra-Articular, Knee Joint pathology, Knee Joint physiopathology, Magnetic Resonance Imaging, Male, Middle Aged, Severity of Illness Index, Spondylitis, Ankylosing complications, Spondylitis, Ankylosing physiopathology, Sulfasalazine therapeutic use, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Knee Joint drug effects, Spondylitis, Ankylosing drug therapy
Abstract

Objective: We describe a series of cases to evaluate the effect of intraarticular infliximab in patients with ankylosing spondylitis (AS) with treatment-resistant arthritis, and to consider whether longterm treatment with intravenous infliximab could be avoided in these patients., Methods: Three patients, fulfilling the New York criteria for AS, had relapsing arthritis of the knee, despite nonsteroidal antiinflammatory drugs, sulfasalazine, and multiple intraarticular (IA) injections of corticosteroids. Since the axial disease or other locomotor manifestations did not justify administration of systemic tumor necrosis factor-a (TNF-a) blocking agents, an IA injection of 100 mg infliximab was administered. The primary endpoint was to examine the efficacy and safety of IA injection of infliximab in AS patients with therapy-refractory arthritis. Before and 4 weeks after IA injection the following variables were evaluated: degree of swelling and tenderness of the affected joint, number of cells/mm3 after joint fluid examination, Bath Ankylosing Spondylitis Disease Activity Index, erythrocyte sedimentation rate, and C-reactive protein. In all 3 cases magnetic resonance imaging (MRI) was performed before injection and 4 weeks after injection., Results: Clinical and biological variables and the MRI findings clearly improved. Remission of the peripheral arthritis was maintained up to 4 months in the first patient and up to 3 months in both others. No important side effects were noted., Conclusion: We observed a beneficial effect of IA infliximab in refractory arthritis in patients with AS. This procedure could be considered an effective and safe treatment for therapy of refractory monoarthritis in AS and an alternative for parenteral TNF-blocking therapy.

Published
2006

9. Diagnostic performance and predictive value of rheumatoid factor, anti-citrullinated peptide antibodies, and the HLA shared epitope for diagnosis of rheumatoid arthritis.

Author

Hoffman IE, Peene I, Pottel H, Union A, Hulstaert F, Meheus L, Lebeer K, De Clercq L, Schatteman L, Poriau S, Mielants H, Veys EM, and De Keyser F

Subjects
Adult, Aged, Aged, 80 and over, Arthritis, Rheumatoid immunology, Epitopes, Follow-Up Studies, Humans, Middle Aged, Peptide Fragments chemistry, Predictive Value of Tests, Retrospective Studies, Arthritis, Rheumatoid diagnosis, Autoantibodies blood, Citrulline chemistry, HLA Antigens immunology, Peptide Fragments immunology, Rheumatoid Factor blood
Published
2005
Full Text
View/download PDF

10. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects.

Author

Mielants H, Veys EM, De Vos M, Cuvelier C, Goemaere S, De Clercq L, Schatteman L, and Elewaut D

Subjects
Adolescent, Adult, Aged, Arthritis, Psoriatic complications, Arthritis, Reactive complications, Chronic Disease, Colonic Diseases diagnosis, Colonic Diseases etiology, Female, Female Urogenital Diseases complications, Histocompatibility Antigens Class I blood, Humans, Ileal Diseases diagnosis, Ileal Diseases etiology, Male, Male Urogenital Diseases, Middle Aged, Prospective Studies, Retrospective Studies, Sigmoidoscopy, Spondylitis drug therapy, Spondylitis, Ankylosing drug therapy, Arthritis, Juvenile complications, Inflammatory Bowel Diseases etiology, Spondylitis complications, Spondylitis, Ankylosing complications
Abstract

Objective: To study prospectively the clinical evolution of different forms of spondyloarthropathy (SpA) (excluding inflammatory bowel disease, IBD): reactive arthritis, undifferentiated SpA, and ankylosing spondylitis (AS)., Methods: Ileocolonoscopy was performed on 217 patients with SpA (149 men, 68 women). They also underwent clinical, laboratory, and radiological examinations. Two to 9 years later, 123 patients (84 men, 39 women) who had been regularly monitored were reviewed and given the same examinations. For the remaining 94 patients clinical data were obtained by telephone., Results: At the time of clinical review, 53 (43%) of the regularly monitored patients were in clinical remission. The remission rate was higher in patients with non-ankylosing spondylitis SpA (non-As-SpA) than in patients with AS (19%). Fourteen patients with non-AS-SpA had developed AS; 4 of them also had IBD. IBD was also found in 4 patients with AS and in 3 patients from the telephone group. The prevalence of HLA-B27 was significantly higher in all SpA subgroups, while HLA-BW62 was elevated in the undifferentiated SpA. At review, HLA-B27 was significantly more prevalent in patients with persistent locomotor inflammation compared to patients in clinical remission, while HLA-BW62 was predominant in the latter group., Conclusion: Patients with SpA, especially those with non-AS-SpA, have a good longterm prognosis. However, patients with non-AS-SpA may develop AS. Six percent of the patients with SpA in whom manifestations of IBD are absent will develop this disease. This confirms the hypothesis that some of these patients with SpA initially have a form of subclinical Crohn's disease, of which locomotor inflammation is the only clinical expression. HLA-B27 positivity predisposes to a more severe course of locomotor inflammation, while HLA-BW62 has a protective effect but is associated with gut inflammation.

Published
1995

11. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint.

Author

Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, Gyselbrecht L, and Elewaut D

Subjects
Adolescent, Adult, Age Factors, Aged, Arthritis, Juvenile complications, Arthritis, Juvenile pathology, Arthritis, Psoriatic complications, Arthritis, Psoriatic pathology, Arthritis, Reactive complications, Arthritis, Reactive pathology, Child, Chronic Disease, Colonic Diseases diagnosis, Colonic Diseases etiology, Female, Female Urogenital Diseases complications, Female Urogenital Diseases pathology, Histocompatibility Antigens Class I blood, Humans, Ileal Diseases diagnosis, Ileal Diseases etiology, Inflammatory Bowel Diseases etiology, Joint Diseases complications, Male, Male Urogenital Diseases, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Sigmoidoscopy, Spondylitis, Ankylosing complications, Colon pathology, Ileum pathology, Inflammatory Bowel Diseases pathology, Joint Diseases pathology, Spondylitis, Ankylosing pathology
Abstract

Objective: To study prospectively the clinical evolution of different forms of spondyloarthropathy (SpA) in relation to the evolution of gut histology in consecutive ileocolonoscopic biopsy specimens., Methods: Ileocolonoscopy was performed in 49 patients with SpA (34 men, 15 women). They also underwent clinical, laboratory, and radiological examinations. Two to 9 years later, a 2nd and sometimes a 3rd or 4th ileocolonoscopy was performed, and the other examinations were repeated., Results: At first ileocolonoscopy, 34 patients (69%) showed inflammatory gut lesions. At the 2nd ileocolonoscopy, 16 patients (32%) were in clinical remission; none were found to have inflammatory gut lesions. Of the 33 patients with persistent locomotor inflammation, 14 had persistent inflammatory gut lesions, predominantly the chronic type. Of these 14 patients, 6 had developed inflammatory bowel disease (IBD). None of the 15 patients with an initially normal gut histology had gut inflammation at 2nd examination. Of the 9 with initially acute lesions, 3 developed chronic lesions (1 Crohn's disease). Initial chronic lesions in 25 patients persisted in 9, of whom 5 had developed IBD. Seven of the 19 patients with non-SpA ankylosing spondylitis (non-AS-SpA) developed ankylosing spondylitis (AS); all had initially presented inflammatory gut lesions, which persisted at 2nd examination. In the 11 patients with more than 2 consecutive ileocolonoscopies, clinical remission was always associated with normal gut histology, and flares of the joint disease were related temporally to the reappearance of gut inflammation., Conclusion: This study demonstrates the close relationship between gut and locomotor inflammation in SpA. Clinical remission was always associated with normal gut histology, whereas active locomotor inflammation was usually associated with the presence of gut inflammation. Absence of gut inflammation in the SpA is a good prognostic indicator, since gut inflammation or IBD never develops in these patients. Evolution of non-AS-SpA to full blown AS or of uncomplicated SpA to a form of IBD was always associated with gut inflammation at disease onset.

Published
1995

12. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects.

Author

Mielants H, Veys EM, Cuvelier C, De Vos M, Goemaere S, De Clercq L, Schatteman L, and Elewaut D

Subjects
Adolescent, Adult, Aged, Arthritis, Juvenile complications, Arthritis, Juvenile pathology, Arthritis, Psoriatic complications, Arthritis, Psoriatic pathology, Arthritis, Reactive complications, Arthritis, Reactive pathology, Biopsy, Chronic Disease, Colonic Diseases diagnosis, Colonic Diseases etiology, Female, Female Urogenital Diseases complications, Female Urogenital Diseases pathology, Histocompatibility Antigens Class I blood, Humans, Ileal Diseases diagnosis, Ileal Diseases etiology, Inflammatory Bowel Diseases etiology, Male, Male Urogenital Diseases, Middle Aged, Prohibitins, Prospective Studies, Risk Factors, Sigmoidoscopy, Spondylitis, Ankylosing complications, Colon pathology, Ileum pathology, Inflammatory Bowel Diseases pathology, Spondylitis, Ankylosing pathology
Abstract

Objective: To study prospectively the clinical evolution of different forms of spondyloarthropathy (SpA) in relation to the type of gut histology in ileocolonoscopic biopsy specimens., Methods: Ileocolonoscopy was performed in 217 patients with SpA (149 men, 68 women). Three types of gut histology (normal gut histology and acute and chronic inflammatory gut lesions) were found. Clinical, laboratory, and radiological examinations were performed at start and 2 to 9 years later in 123 patients who were regularly monitored. For the remaining 94 patients clinical data were obtained by telephone., Results: Of the 123 patients monitored regularly, 40 (32%) had normal gut histology, and 28 (23%) had acute and 55 (45%) chronic inflammatory gut lesions. Acute lesions were preferentially found in patients with non-ankylosing spondylitis SpA (non-AS-SpA). In the groups with normal gut histology and with chronic gut inflammation, patients with ankylosing spondylitis (AS) and non-AS-SpA were present in equal numbers. At review, clinical evolution was identical in the 3 histological subgroups. Eight patients developed idiopathic inflammatory bowel disease (IBD), one with initially acute gut inflammation, 7 with initially chronic gut inflammation. All had active AS at review. Fourteen patients with non-AS-SpA developed AS; 13 of them had initially presented inflammatory gut lesions. Three patients in the telephone group also developed IBD; all had active AS at review and initially presented chronic inflammatory gut lesions. Persistently high inflammatory serum variables, HLA-B27 negativity in the presence of sacroiliitis or AS, and inflammatory gut lesions at the first ileocolonoscopy indicate patients with SpA are at risk for developing IBD., Conclusion: Gut inflammation, mainly subclinical, could be demonstrated in 68% of patients with SpA. Acute gut inflammation was predominant in patients with reactive arthritis (ReA). The evolution to clinical remission was not influenced by the presence or the type of gut inflammation at start. Patients with non-AS-SpA with inflammatory gut lesions have greater risk of developing AS. One patient with Yersinia induced ReA developed AS and IBD. In total, 11 patients (66%) developed IBD, all initially presenting inflammatory gut lesions. Ten had chronic gut lesions, suggesting this type of gut inflammation is related to the inflammation of Crohn's disease. This type of gut inflammation, the persistence of high inflammatory serum variables, and the absence of HLA-B27 in patients with AS are risk factors for developing IBD.

Published
1995

13. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopic study.

Author

Schatteman L, Mielants H, Veys EM, Cuvelier C, De Vos M, Gyselbrecht L, Elewaut D, and Goemaere S

Subjects
Adolescent, Adult, Aged, Arthritis, Psoriatic immunology, Enteritis epidemiology, Female, HLA Antigens analysis, Humans, Male, Middle Aged, Prevalence, Prospective Studies, Arthritis, Psoriatic complications, Arthritis, Psoriatic pathology, Colon pathology, Colonoscopy, Enteritis etiology, Ileum pathology
Abstract

Objective: Some forms of psoriatic arthritis (PsA) are classified as spondylarthropathy, and subclinical gut inflammation is found in spondylarthropathies. Our study was designed to determine if inflammatory gut lesions were also present in PsA, and if the prevalence of subclinical gut involvement was different in the subgroups of this disease. The relationship with HLA subtypes was also determined., Methods: Ileocolonoscopy was performed on 64 patients with PsA (37 men, 27 women)., Results: Inflammatory gut lesions were found in 10 of the 64 patients (16%): in 3 of the 15 patients (20%) with oligoarthritis and in 7 of the 23 patients (30%) with axial involvement. None of the 26 patients with polyarthritis showed these lesions. The prevalence of HLA-B27, Bw62, and B17 was significantly raised in our total group of patients with PsA. HLA-B27 and Bw62 were significantly more prevalent in patients with gut inflammation, 60 and 50%, respectively., Conclusion: Gut inflammation is only present in PsA subgroups that belong to the spondylarthropathy concept. This suggests that the gut plays a role in the pathogenesis of locomotor inflammation in these subgroups. The prevalence of gut inflammation in psoriatic spondylarthropathy is significantly lower than in nonpsoriatic spondylarthropathies. Consequently, not only the gut but also the skin may be a portal of entry for causative antigens in PsA.

Published
1995

15. Proteoglycan metabolism in isolated chondrocytes from human cartilage and in short-term tissue-cultured human articular cartilage.

Author

Verbruggen G, Veys EM, Malfait AM, Schatteman L, Wieme N, Heynen G, Vanhoutte V, and Broddelez C

Subjects
Cells, Cultured, Culture Techniques, Humans, Hyaluronic Acid metabolism, Cartilage cytology, Cartilage, Articular cytology, Piroxicam pharmacology, Proteoglycans metabolism
Abstract

The effect of piroxicam on proteoglycan metabolism of human cartilage cells was investigated in two in vitro models. Cells or tissue samples were obtained from six different donors. Piroxicam levels used in the test systems ranged from 2 to 6 micrograms r/ml and were comparable with serum concentrations in humans after oral intake. Piroxicam increased the synthesis rates of proteoglycan in some batches of isolated and monolayer-cultured chondrocytes and in tissue-cultured articular cartilage. The fact that this increase in the synthesis of proteoglycan was restricted to some of the donors whereas isolated cells or tissue samples from other individuals remained unaffected illustrates the heterogeneity of different human donors. Depression of proteoglycan synthesis in the presence of the drug was not observed.

Published
1989

16. Proteoglycan metabolism in tissue cultured human articular cartilage. Influence of piroxicam.

Author

Verbruggen G, Veys EM, Malfait AM, Cochez P, Schatteman L, Wieme N, Heynen G, and Broddelez C

Subjects
Adolescent, Adult, Cartilage, Articular drug effects, Culture Media, Culture Techniques, Female, Humans, Knee Joint, Male, Middle Aged, Sulfur Radioisotopes, Time Factors, Cartilage, Articular metabolism, Piroxicam pharmacology, Proteoglycans biosynthesis
Abstract

Proteoglycan metabolism was investigated in longterm tissue cultured human cartilage. Visually intact cartilage from adult donors showed improving accumulation rates for 35sulfate labelled proteoglycans over a 6-week period. The loss of newly synthesized molecules in the nutrient culture media was low and constant. Fibrillated cartilage from a 17-year-old male showed higher basal 35S incorporation rates and the proportions of 35S proteoglycan aggregates were higher than in normal tissue. These observations may reflect the immature status of the tissue or an attempt at repair. However samples lost increasing amounts of 35S proteoglycans in the incubation media. This material appeared to be monomeric proteoglycan. The amount of 35S activity retained in the fibrillated tissue matrix fell during culture as did the proportion of proteoglycan aggregates. Thus catabolic events were postulated in these fibrillated cartilage samples. When piroxicam was added to the incubation media more newly synthesized proteoglycans were retained in the intercellular matrix of the fibrillated samples. Increased accumulation of 35S activity was seen in some of the batches of visually intact cartilage.

Published
1989

Catalog

Books, media, physical & digital resources
See catalog results